

In the claims:

1. (withdrawn)
2. (withdrawn)
3. (withdrawn)
4. (withdrawn)
5. (withdrawn)
6. (currently amended) A An aqueous pre-treatment liquid used in for use in preparation of a pre-treated recording medium for use in an offset printing plate applications using having a porous recording surface, for use with direct inkjet CTP,
said pre-treatment liquid consisting of:
an ion donor, selected from the group of an inorganic acid and a polyvalent metallic salt, for providing mechanical stability of a printing plate image formed by a plurality of inkjet dots
and at least one of:
a polymer swelling reagent, selected from the group of N-methyl pyrrolidone, organic esters, ketones and cyclic ethers,
and a coalescence reagent, selected from the group of butyl glycol and glycol ethers for creation of a stable dot shape[.],
such that when said pre-treatment liquid is applied to said printing plate, it becomes physically localized in the porous recording surface,
said ion donor binds chemically to the inkjet drops,
and said at least one of a polymer swelling reagent and a coalescence reagent diffuses within the CTP liquid,
thereby providing mechanical stability to each of the inkjet drops and enabling the formation of a stable dot shape, having good film properties and very good adhesion to said pre-treated recording surface, resulting

in smaller dot size and subsequent improved image quality.

7. (original) The pre-treatment liquid of claim 6 wherein said liquid is a solution.
8. (currently amended) The pre-treatment liquid of claim 6, wherein said liquid is an organic phase emulsion in water, wherein at least one of said swelling reagent and said coalescence reagent are in said organic phase which is emulsified in water containing said ~~polyvalent~~ metallic salt ion donor.
9. (canceled)
10. (currently amended) The pre-treatment liquid of claim ~~9~~ 6 wherein said inorganic acid is comprised of an acid from the group of phosphoric, sulfuric, nitric and hydrochloric acid.
11. (currently amended) The pre-treatment liquid of claim ~~9~~ 6 where the pH is approximately between 0 and 4.
12. (currently amended) The pre-treatment liquid of claim ~~9~~ 6 where the pH is approximately between 1 and 3.
13. (canceled)
14. (currently amended) The pre-treatment liquid of claim ~~13~~ 6 wherein said polyvalent metallic salt includes at least one of divalent and trivalent metallic cations.

15. (original) The pre-treatment liquid of claim 14 wherein said metallic cations are chosen from the group consisting of: Ca^{+2} , Zn^{+2} , Ba^{+2} , Mg^{+2} , Al^{+3} , Fe^{+3} and Cr^{+3} .
16. (original) The pre-treatment liquid of claim 15 wherein said cation comprises between approximately 2% to approximately 25% of said pre-treatment liquid.
17. (original) The pre-treatment liquid of claim 15 wherein said cation comprises between approximately 3% to approximately 20% of said pre-treatment liquid.
18. (currently amended) The pre-treatment liquid of claim ~~13~~ 6 wherein said polyvalent metallic salt is comprised of an anion from the group of: Cl^- , I^- , Br^- , NO_3^- , HCOO^- , $\text{CH}_3\text{CH}_2\text{COO}^-$ and CH_3COO^- .
19. (canceled)
20. (original) The pre-treatment liquid of claim 6 wherein said polymer swelling reagent comprises between approximately 0.1% to approximately 15% by weight of said pre-treatment liquid.
21. (original) The pre-treatment liquid of claim 6 wherein said polymer swelling reagent comprises between approximately 0.5% to approximately 7.5% by weight of said pre-treatment liquid.
22. (canceled)
23. (original) The pre-treatment liquid of claim 6 wherein said coalescence reagent comprises between

approximately 0.1% to approximately 12% by weight of said pre-treatment liquid.

24. (original) The pre-treatment liquid of claim 6 wherein said coalescence reagent comprises between approximately 0.5% to approximately 6% by weight of said pre-treatment liquid.